GeNeuro | CHF 6.7 million for the development of COVID-19 medicines
Share this article
GeNeuro received CHF 6.7 million in funding for the development of temelimab against Long-COVID
GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases based in Geneva (Switzerland), with final Phase II results in multiple sclerosis expected in March 2022, announced that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health (FOPH) and that it will receive in this regard a grant of 6.7 million Swiss francs (€6.4 million) to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric (“neuropsychiatric”) symptoms.
Today, GeNeuro is able to test the presence of W-ENV in the blood of patients suffering from Long-COVID, and is developing temelimab, a specific anti-W-ENV antibody, already being tested against neurodegeneration in multiple sclerosis. The clinical trial supported by the FOPH will be a double-blind, randomised, placebo-controlled clinical study on Long-COVID patients with severe neuropsychiatric symptoms that prevent them from continuing their daily and professional activities. This study will start in the spring of 2022.
GeNeuro’s mission is to develop safe and effective treatments for neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralising causative factors induced by human endogenous retroviruses (HERVs), which represent 8% of the human genome. Based in Geneva, Switzerland, and with an R&D center in Lyon, France, GeNeuro holds the rights to 17 patent families that protect its technology.